For: | Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190 [PMID: 26839641 DOI: 10.4254/wjh.v8.i3.183] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v8/i3/183.htm |
Number | Citing Articles |
1 |
Tatsuo Kanda. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatology International 2017; 11(1): 38 doi: 10.1007/s12072-016-9749-y
|
2 |
Temi Lampejo. Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of in vitro and in vivo Evidence. Journal of Clinical and Experimental Hepatology 2022; 12(4): 1225 doi: 10.1016/j.jceh.2022.02.003
|
3 |
Seema Patel. In silico analysis of Hepatitis C virus (HCV) polyprotein domains and their comparison with other pathogens and allergens to gain insight on pathogenicity mechanisms. Computational Biology and Chemistry 2016; 65: 91 doi: 10.1016/j.compbiolchem.2016.10.006
|
4 |
Shu-Mei Tsai, Jung-Ta Kao, Yun-Fang Tsai. How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study. BMC Health Services Research 2016; 16(1) doi: 10.1186/s12913-016-1503-6
|
5 |
Anjar Hermadi Saputro, Tasia Amelia, Andhika Bintang Mahardhika, Aty Widyawaruyanti, Tutik Sri Wahyuni, Adita Ayu Permanasari, Aluicia Anita Artarini, Daryono Hadi Tjahjono, Sophi Damayanti. Alpha-mangostin, piperine and beta-sitosterol as hepatitis C antivirus (HCV): In silico and in vitro studies. Heliyon 2023; 9(9): e20141 doi: 10.1016/j.heliyon.2023.e20141
|
6 |
Omayma A. Ragab AboZaid, Mohamed K. Mahfouz, Omneia M. Abdel hammed, Abdel Maksoud H.A, Ali W. Elwan, Omneia Elsaid Abdallah, Mohamed G. Elharrif. Sofosbuvir plus ribavirin combination regimen boost liver functions and antioxidant profile in hepatitis C virus patients. Microbial Pathogenesis 2021; 150: 104740 doi: 10.1016/j.micpath.2021.104740
|
7 |
Mauro Safir Filho, Anthony R. Martin, Rachid Benhida. Assessment of new triplet forming artificial nucleobases as RNA ligands directed towards HCV IRES IIId loop. Bioorganic & Medicinal Chemistry Letters 2017; 27(8): 1780 doi: 10.1016/j.bmcl.2017.02.061
|
8 |
Elisa Pileggi, Michaela Serpi, Fabrizio Pertusati. Preparation of Pyrimidine Alkenyl Acyclic Nucleoside Phosphonoamidates. Current Protocols in Nucleic Acid Chemistry 2018; 74(1) doi: 10.1002/cpnc.56
|
9 |
Maaike Everts, Tomas Cihlar, J. Robert Bostwick, Richard J. Whitley. Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. Annual Review of Pharmacology and Toxicology 2017; 57(1): 155 doi: 10.1146/annurev-pharmtox-010716-104533
|
10 |
Elisa Pileggi, Michaela Serpi, Graciela Andrei, Dominique Schols, Robert Snoeck, Fabrizio Pertusati. Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. Bioorganic & Medicinal Chemistry 2018; 26(12): 3596 doi: 10.1016/j.bmc.2018.05.034
|
11 |
Christine Y. Chang, Pauline Nguyen, An Le, Changqing Zhao, Aijaz Ahmed, Tami Daugherty, Gabriel Garcia, Glen Lutchman, Radhika Kumari, Mindie H. Nguyen. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine 2017; 96(6): e6128 doi: 10.1097/MD.0000000000006128
|
12 |
Eldar Abdurakhmanov, Sara Øie Solbak, U. Danielson. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Viruses 2017; 9(6): 151 doi: 10.3390/v9060151
|
13 |
Věra Schrenková, Josef Kapitán, Petr Bouř, Argyro Chatziadi, Adam Sklenář, Jakub Kaminský. Sofosbuvir Polymorphs Distinguished by Linearly and Circularly Polarized Raman Microscopy. Analytical Chemistry 2024; doi: 10.1021/acs.analchem.4c03573
|
14 |
Clara C. Posthuma, Aartjan J.W. te Velthuis, Eric J. Snijder. Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes. Virus Research 2017; 234: 58 doi: 10.1016/j.virusres.2017.01.023
|